Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Phase III Trial Of Bayer/Onyx Regorafenib Stopped Early For Efficacy

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Interim analysis revealed the trial in advanced metastatic colorectal cancer had already met the overall survival endpoint.

You may also be interested in...

Partners Onyx And Bayer Settle Next-Gen Nexavar Lawsuit, Enter New Deal

Onyx dropped its lawsuit against partner Bayer in exchange for an agreement that lets it share the financial rewards of the compound at the heart of the controvers, regorafenib, now in Phase III for oncology indications.

Next Step for Onyx Pharma: 2011 Is Defining Year

Onyx Pharmaceuticals Inc.’s growing pipeline, including one high-profile compound finishing successful Phase II clinical trials, appears to be finally moving the company beyond its considerable reliance on its flagship cancer drug Nexavar (sorafenib).

Sanofi's Cabazitaxel Swiftly Approved, But Launch Date Is Uncertain

Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts